Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × trametinib × 90 days × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Melanoma 12 Carcinoma, Non-Small-Cell Lung 8 Multiple Myeloma 6 Glioma 6 Colorectal Neoplasms 6 Hematologic Neoplasms 4 Neoplasm Metastasis 3 Lymphoma 3 Thyroid Neoplasms 2 Thyroid Carcinoma, Anaplastic 2 Neurofibromatosis 1 2 Neoplasms 2 Lung Neoplasms 2 Histiocytosis, Langerhans-Cell 2 Glioblastoma 2 Astrocytoma 2 Uveal Melanoma 1 Thyroid Cancer, Papillary 1 Solid Tumors, KRAS Mutation; SOS1 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibroma, Plexiform 1 Neurocytoma 1 Neuroblastoma 1 Neoplasms by Site 1

Interventions

Dexamethasone 15 Cyclophosphamide 12 pembrolizumab 11 Rituximab 11 venetoclax 10 pomalidomide 10 fludarabine 9 Lenalidomide 8 Calcium Dobesilate 7 glofitamab 6 Gemcitabine 6 Cytarabine 6 carfilzomib 5 Temozolomide 5 Nivolumab 5 Etoposide 5 Bevacizumab 5 selinexor 4 ruxolitinib 4 obinutuzumab 4 daratumumab 4 Doxorubicin 4 Carboplatin 4 Capecitabine 4 Bortezomib 4 Azacitidine 4 zanubrutinib 3 tisagenlecleucel 3 elotuzumab 3 blinatumomab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡